Genentech’s Rituxan is a non-Hodgkin’s lymphoma treatment and a rheumatoid arthritis drug that is linked to potentially fatal adverse effects. The FDA issued a health advisory warning of the possible risk of a fatal brain infection called progressive multifocal leukoencephalopathy (PML) in patients who were treated with this drug.
PML is a fatal viral disease characterized by progressive inflammation or damage to some part of the brain. PML symptoms include loss of vision, mental deterioration, ataxia, speech disturbances, seizures, dysphasia, and memory failure.
Rituxan is a cancer drug made to interfere with cancer cell’s growth. Oftentimes, it is combined with other drugs to treat symptoms of rheumatoid arthritis.
A recent study found that 57 people were diagnosed with PML after given Rituxan. In 2010, a patient filed lawsuit after he suffered from a life-threatening infection due to his usage of Rituxan. This infection led to his becoming a quadriplegic.
Those who are affected by the serious adverse effects of Rituxan are encouraged to seek advice from lawyers to see learn about their legal options. You may qualify for compensation for damages caused by the drug. The manufacturer could be held liability for expenses related to Rituxan harmful side effects.